We recently showed the ability of lovastatin to inhibit the function of the epidermal growth factor receptor (EGFR) and its downstream signaling of the phosphatidylinositol-3 kinase/ AKT pathway. Combining lovastatin with gefitinib, a potent EGFR inhibitor, induced synergistic cytotoxicity in various tumor-derived cell lines. In this study, lovastatin treatment was found to inhibit ligand-induced EGFR dimerization in squamous cell carcinoma cells and its activation of AKT and its downstream targets 4E-binding protein 1 and S6 kinase 1. This inhibition was associated with global protein translational inhibition shown by a decrease in RNA associated polysome fractions. The effects of lovastatin on EGFR function were reversed by the addition of geranylgeranyl pyrophosphate, which functions as a protein membrane anchor. Lovastatin treatment induced actin cytoskeletal disorganization and the expression of geranylgeranylated rho family proteins that regulate the actin cytoskeleton, including rhoA. Lovastatin-induced rhoA was inactive as EGF stimulation failed to activate rhoA and inhibition of the rho-associated kinase, a target and mediator of rhoA function, with Y-27632 also showed inhibitory effects on EGFR dimerization. The ability of lovastatin to inhibit EGFR dimerization is a novel exploitable mechanism regulating this therapeutically relevant target. To explore the potential clinical significance of this combination, we evaluated the effect of statin on the overall survival (OS) and disease-specific survival (DSS) of patients with advanced nonsmall-cell lung cancer enrolled in the NCIC Clinical Trials Group phase III clinical trials BR21 (EGFR tyrosine kinase inhibitor erlotinib versus placebo) and BR18 (carboplatin and paclitaxel with or without the metalloproteinase inhibitor BMS275291). In BR18, use of statin did not affect OS or DSS. In BR21, patients showed a trend for improvement in OS (HR: 0.69, P ¼ 0.098) and DSS (HR: 0.62, P ¼ 0.048), but there was no statin Â treatment interaction effect (P ¼ 0.34 and P ¼ 0.51 for OS and DSS, respectively).
Introduction
Epithelial malignancies such as squamous cell carcinomas (SCCs) have very limited treatment options when presenting as metastatic disease (Greenlee et al., 2000; Breathnach et al., 2001) . Receptor tyrosine kinases, particularly the epidermal growth factor receptor (EGFR), have been shown to have significant roles in the pathogenesis of SCC (Nicholson et al., 2001 ). As such, targeting EGFR function has been an intensive focus of anticancer therapeutic approaches. Tyrosine kinase inhibitors prevent the autophosphorylation of the intracellular tyrosine kinase domain of receptor tyrosine kinases (Mendelsohn and Baselga, 2000; Cabebe and Wakelee, 2007) . These molecules are generally reversible competitors with ATP for binding to the intracellular catalytic domain of the tyrosine kinase (Mendelsohn and Baselga, 2000; Cabebe and Wakelee, 2007) . These selective inhibitors of receptor tyrosine kinases represent attractive therapeutic approaches (Herbst, 2002 (Herbst, , 2003 Thomas et al., 2003) . As such, tyrosine kinase inhibitors, including gefitinib and erlotinib, have been developed targeting the EGFR and have shown promising but limited clinical activity (Herbst, 2002 (Herbst, , 2003 .
Activation of the EGFR is stimulated by ligand binding, which results in receptor dimerization and its subsequent autophosphorylation required to activate its downstream signaling targets that mediate its effects on growth, differentiation, migration and cell survival (Mendelsohn and Baselga, 2000; Boulougouris and Elder, 2001 ). Levels of these receptors at the cell surface, affinity for ligand binding, its dimerization partners and activity of attenuation mechanisms that include receptor internalization and phosphatase activity regulate the extent of EGFR autophosphorylation and activation (Mendelsohn and Baselga, 2000) . Dimerization of EGFR after ligand binding is critical for the autophosphorylation and activation of its downstream signaling cascades. EGFR can either form homodimers or heterodimers, in which case Erb2 is the most common binding partner of EGFR (Sako et al., 2000) . Ligandactivated EGFR is rapidly internalized into early endosome vesicles as a primary mechanism to attenuate its signal (Mendelsohn and Baselga, 2000) . Receptor dimerization and internalization are linked because of the necessity of dimerization to induce receptor autophosphorylation and the recognition and docking of the internalization machinery to specific autophosphorylation site(s) (Mendelsohn and Baselga, 2000) .
EGFR autophosphorylation sites when activated are the biochemical triggers that start a series of downstream signaling cascades that regulate the effects of this receptor on cell proliferation and cell survival, including the activation of the phosphatidylinositol-3 kinase (PI3K)/AKT pathways (Mendelsohn and Baselga, 2000; Dann and Thomas, 2006) . Besides promoting cell survival, signaling by the PI3K/AKT pathway also affects mRNA translation through the activation of mammalian target of rapamycin (mTOR) and the subsequent phosphorylation of eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) and S6 kinase 1 (S6K1; Dann and Thomas, 2006) . S6 is a ribosomal protein that is a component of the 40S subunit (Dann and Thomas, 2006) . Hyperphosphorylated 4EBP1 is released from eukaryotic translation initiation factor 4E (eIF4E), resulting in enhanced capdependent translation (Dann and Thomas, 2006) . The phosphorylation of 4EBP1 and S6K1 is stimulated by serum, insulin and growth factors such as EGF.
Statins are potent inhibitors of 3-hydroxy-3-methyl glutaryl coenzyme A reductase, the rate-limiting enzyme of the mevalonate pathway, and are widely used in hypercholesterolemia treatments (Corsini et al., 1995) . The mevalonate pathway end products are critical for many different cellular functions and include cholesterol, dolichol, ubiquinone, isopentenyladenine, geranylgeranyl pyrophosphate (GGPP) and farnesyl pyrophosphate (FPP; Goldstein and Brown, 1990) . Geranylgeranyl transferase and farnesyl transferase use GGPP and FPP, which function as membrane anchors, for posttranslational modifications of a wide variety of small guanosine-5 0 -triphosphate-binding proteins that regulate cell proliferation, intracellular trafficking and cell motility (Gibbs et al., 1994; Sebti and Hamilton, 1997) . 3-hydroxy-3-methyl glutaryl coenzyme A reductase and EGFR-targeted therapies may be linked because of the potential of mevalonate metabolites to affect the function of the EGFR signaling pathway. For example, FPP-and GGPP-modified proteins include the ras, rho and rab families that have critical roles in transducing EGFR signals (Pruitt and Der, 2001; Seabra et al., 2002) .
In this study, we show the ability of lovastatin to inhibit EGFR dimerization, which results in inhibition of ligand-activated AKT along with its downstream targets that regulate protein translation initiation. These inhibitory effects of lovastatin on EGFR activity were mediated by its ability to effectively target the function of rhoA and may have clinical implications.
Results

Lovastatin inhibits EGFR dimerization and internalization
First, we determined the effects of lovastatin treatment on ligand binding-induced dimerization of the EGFR by performing crosslinking experiments (Sorokin et al., 1994) . SCC9 cells were treated with control and 10 mM lovastatin for 24 h and then stimulated with 50 ng/ml of EGF for 0, 5,10 and 30 min. Using western blot analysis, dimers were visualized as 4300 kD bands, with monomers serving as loading control. As shown in Figure 1a , lovastatin treatment inhibited ligand-stimulated EGFR dimerization in SCC9 cells. To further examine whether lovastatin also regulates the internalization of the EGFR ligand complex, we performed Pinpoint Cell Surface Protein Isolation for proteins localized on the cell surface. Cell surface proteins were marked by biotinylation and isolated using immobilized avidin before westerns blot analysis for EGFR expression. As shown in Figure 1b , control cells were found to have relatively high amounts of EGF receptor expressed on the surface of the cell. Stimulation with EGF ligand decreased the levels of EGFR on the cell surface. In cells treated for 24 h with 10 mM lovastatin, although EGFR levels were reduced overall, ligand stimulation did not affect EGFR surface expression on SCC9 cells, indicating inhibition of internalization.
Transferrin receptors are known to undergo constitutive internalization and recycling (Oksvold et al., 2001) , whereas the receptors for growth factors, such as EGFR, require ligand binding for internalization (Oksvold et al., 2001) . To further confirm whether lovastatin treatment can regulate EGFR internalization, we used Alexa 555-conjugated EGF and rhodamineconjugated transferrin as tagged ligands for their respective receptors. Control and 10 mM lovastatin (24 h)-pretreated SCC9 cells were incubated for 15 min with 50 nM fluorescently labeled EGF and transferrin, washed, fixed and visualized by fluorescent microscopy. In control SCC9 cells, transferrin and EGF were readily internalized (Figure 1c) . In lovastatin-treated SCC9 cells, transferrin was readily internalized; however, EGF remained at the cell surface ( Figure 1c) . These results indicate a lack of internalization of EGF in lovastatin-treated SCC9 cells.
Lovastatin inhibits downstream EGF signaling pathways Next, we evaluated the effect of lovastatin treatment on the PI3K/AKT pathways signaling cascade triggered by EGFR, which has a role in its cell survival response (Boulougouris and Elder, 2001 ). Serum-starved SCC9 and SCC25 cells were treated with 0, 1, 10 and 25 mM lovastatin for 24 h, followed by 50 ng/ml of EGF stimulation for 30 min. Functional activation of AKT was evaluated by western blot analysis, using a phospho-specific antibody. Lovastatin treatments inhibited activation of AKT in a dose-dependent manner that was readily detectable at a dose of 1 mM (Figure 2a) , a clinically relevant dose of lovastatin (Thibault et al., 1996) . The effects of AKT on regulation of protein translation are largely regulated by its downstream target mTOR. mTOR phosphorylates S6K1, and active S6K1 stimulates protein synthesis through activation of the S6 ribosomal protein (Pallet et al., 2006) . 4EBP1 directly interacts with eIF4E, which is rate limiting for 40S ribosomal recruitment to mRNAs. On phosphorylation by mTOR, 4EBP1 releases eIF4E, activating mRNA translation (Pallet et al., 2006) . Lovastatin treatment (same conditions as above) in SCC9 and SCC25 cells inhibited EGF activation of S6K1 and 4EBP1, as evaluated by phosphorylation levels of these proteins (Figure 2a) . mTOR has recently emerged as an attractive downstream AKT therapeutic target, particularly in combination with EGFR-tyrosine kinase inhibitors (Doherty et al., 2006) . In this study, we demonstrate by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide analysis that both rapamycin (10 nM) and lovastatin (10 mM), at therapeutically relevant doses (Thibault et al., 1996; Doherty et al., 2006) , augmented the cytotoxic effects of gefitinib in SCC9 and SCC25 cells (Figure 2b) . Together, these results show that lovastatin treatment can readily inhibit AKT and its downstream targets in SCC cells.
Lovastatin treatment inhibits global protein translation
To assess whether lovastatin treatment of SCC25 cells attenuates global protein translation, we fractionated cell lysates by sucrose density gradient centrifugation. In Figure 3a , the optical density profiles of typical sucrose gradients are shown. The top of the gradient contains free mRNAs and ribosomal subunits (40S, 60S and 80S), whereas the bottom of the gradient contains mRNAs associated with polysomes (Blais et al., 2004) . Analysis of the optical density profiles showed a reduction in the relative amount of mRNAs associated with polysomal fractions in lovastatin-treated cells, thereby indicating an overall attenuation of protein synthesis in lovastatin (10 mM, 24 h)-treated SCC25 cells and in cells treated with lovastatin in combination with 50 ng/ml of EGF (Figure 3a) . We next performed quantitative reverse transcriptase PCR analysis to compare the expression profile of (activation of transcription factor) ATF3 and GAPDH (Figure 3b ) mRNA in monosome-and polysome-enriched fractions. It has been shown before that increased ATF3 expression is an indication of attenuation of protein translation during stress (Niknejad et al., 2007) . We found that ATF3 mRNA (Figure 3b ) shifted toward the heavier polysome fractions in lovastatin-treated cells. In contrast, the distribution of GAPDH mRNAs shifted to the lighter monosome fractions (Figure 3b ).
Geranylgeranyl reverses the inhibitory effect of lovastatin on EGFR activation Lovastatin (10 mM, 24 h)-treated SCC9 cells were coincubated with 100 mM mevalonate, 10 mM GGPP, 10 mM FPP, 10 mM dolichol phosphate or 10 mM ubiquinone. The coadministration of mevalonate, GGPP and FPP mitigated the inhibitory effects of lovastatin on EGFinduced EGFR activation. Both the pan antiphosphotyrosine antibody (PY20) and the antiphosphotyrosine antibody specific for amino-acid residue at 1068 of the EGFR showed similar results ( Figure 4a ). We further examined the effects of adding back mevalonate or GGPP on EGFR dimerization. Mevalonate (100 mM) and GGPP (10 mM) addition to lovastatin (10 mM, 24 h)-treated SCC9 or SCC25 cells restored EGF-induced EGFR dimerization (Figure 4b ). These results indicate that the ability of lovastatin to inhibit the dimerization/ activation of EGFR is through its targeting of the mevalonate pathway and that this effect is likely regulated by geranylgeranylated proteins.
Lovastatin induces cytoskeletal disorganization with increased expression of inactive rhoA
The rho-associated coiled-coil-forming protein serine/ threonine kinase (ROCK) family, composed of ROCK and the closely related p160ROCK, is a downstream target of rhoA that transduces rho activation into stress fiber formation and leads to assembly of focal adhesions (Amano et al., 2000) . In this study, we used a specific inhibitor of the ROCK family kinases, Y-27632 (Darenfed et al., 2006) . Actin architecture was visualized with rhodamine-conjugated phalloidin, which has a high affinity for F-actin following 10 mM lovastatin and 1 mM Y-27632 treatment for 24 h in SCC9, SCC25 and NIH3T3 murine fibroblasts. Although the pattern of actin staining differed, stress fiber and focal adhesions were inhibited by both agents and were particularly evident in NIH3T3 cells (Figure 5a ).
The geranylgeranylated rho proteins regulate actin cytoskeleton and agents that affect actin polymerization have been shown to inhibit EGFR function as well (Lunn et al., 2000) . RhoA, rac1 and cdc42 have significant roles in actin cytoskeleton reorganization (Hall, 2005) . In SCC9 and SCC25 cells, 24 h treatment with 10, 20 and 50 mM of lovastatin induced significant expression of rhoA and cdc42, but not of rac1, as assessed by western blot analysis ( Figure 5b ). The induction of rhoA and cdc42 expression in these cell lines was reversed by the coadministration of mevalonate and GGPP (Figure 5b ). Activation of rho proteins has a role in cell-cycle progression by cyclin D1 upregulation (Pruitt and Der, 2001) . In SCC9 and SCC25 cell lines, 24 h lovastatin treatment at 10, 20 and 50 mM showed a dose-dependent downregulation of cyclin D1 protein (Figure 5c ). This effect was reversed by the coadministration of mevalonate and GGPP. Using two-dimensional gel electrophoresis, we showed that lovastatin-induced rhoA showed a slight shift in Cell lysates were collected after treatments for 24 h with control, 1, 10 and 25 mM lovastatin in serumfree media, followed by 50 ng/ml of EGF stimulation for 30 min. the phosphorylation level of AKT decreased with lovastatin treatment in a dose-dependent manner. Expression level of AKT was assayed as the loading control. Phosphorylation levels of S6K1 and 4EBP1 also decreased with lovastatin treatment in a dose-dependent manner. Expression levels of S6K1 and 4EBP1 were assayed as the loading control. (b) Evaluating the cytotoxic effects of treatment of rapamycin and lovastatin in combination with Iressa (gefitinib) in SCC cell lines using 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. Iressa (gefitinib; 0-25mM) was evaluated alone or in combination with 10 nM rapamycin or 10 mM lovastatin. MTT data were normalized to untreated (media alone) cells (representing 100%) and are typical of two independent experiments.
isoelectric focusing than the rhoA in nontreated cells (Figure 5d ). These results mirror previously published data in which rhoA lacked GGPP modification (Cicha et al., 2004) . Furthermore, using a colorimetric rhoA activation assay, we determined the effect of lovastatin on EGF-induced rhoA activation in SCC9 and SCC25 cells. Serum-starved cell extract represents inactive levels of rhoA, whereas 0.2 M guanosine-5 0 -triphosphateloaded extract represents fully active rhoA. As expected, EGF stimulation induced rhoA activity to B70% of the guanosine-5 0 -triphosphate-loaded activity. Lovastatin (10 mM, 24 h) inhibited EGF-induced rhoA activation in both SCC9 and SCC25 cells, whereas coadministration of mevalonate (100 mM) and GGPP (10 mM) reversed the inhibitory effects of lovastatin (Figure 5e ). These results show that lovastatin-induced rhoA is inactive most likely because of the lack of GGPP modification.
Y-27632 inhibits EGF-induced EGFR dimerization and activation
To assess the targeting of the rhoA/ROCK pathway on EGF-induced EGFR activation, we evaluated the effect of Y-27632 treatment. Western blot analysis was used to compare the effects of 10 mM lovastatin treatment for 24 h and 1 mM Y-27632 treatment for 24 h in SCC9 cells. Both agents did not have an effect on endogenous EGFR protein levels ( Figure 6 ). However, Y-27632 treatment of SCC9 cells showed an inhibitory effect similar to lovastatin on EGF-induced EGFR activation, as shown by decreased levels of phosphotyrosine (PY20; Figure 6a ). Both lovastatin and Y-27632 treatments were unaffected by cotreatment with the phosphatase inhibitor sodium orthovanadate (Na 3 OV 4 ; Ostman and Bohmer, 2001) (Figure 6b ). Mevalonate (100 mM) and GGPP (10 mM) coadministration inhibits the effects of lovastatin on EGF-induced EGFR activation, but not Y-27632-treated SCC9 cells (Figures 6c and d) . These interesting results lead us to further investigate the role of Y-27632 on EGFR dimerization. SCC9 cells treated with control and 1 mM Y-27632 for 24 h were stimulated with 50 ng/ml of EGF for 30 min as indicated. In SCC9 cells, Y-27632 treatment significantly decreased the EGFR dimer formation that was not rescued by the coadministration of mevalonate or GGPP (Figure 6e) . These results suggest a model by which lovastatin induces actin disorganization through inhibition of geranylgeranylation of the rho family of proteins, resulting in the inhibition of EGFR dimerization, activation and downstream signaling. Evaluating statin use in patients with advanced non-smallcell lung carcinoma (NSCLC) In exploratory analyses, the association between statin use and overall survival (OS) and disease-specific survival (DSS) in patients with advanced NSCLC was assessed in the NCIC CTG BR.18 (Leighl et al., 2005) and BR.21 (Shepherd et al., 2005) clinical trials. BR.18 was a randomized phase III trial of carboplatin and paclitaxel chemotherapy with or without the matrix metalloproteniase inhibitor BMS 275291. BR.21 was a placebo-controlled randomized phase III trial of erlotinib in patients with advanced NSCLC after chemotherapy failure. A significant improvement in OS for patients randomized to the erlotinib arm was shown (HR ¼ 0.70, log rank Po0.001). In BR.18 and BR.21, the number of patients who received statin at or after randomization was 47 and 28, respectively. In BR.18, there was no difference in OS or DSS (Figure 7a ) for the statin versus no-statin cohort (OS: HR ¼ 0.95, log rank P ¼ 0.75; DSS: HR ¼ 1.02, log rank P ¼ 0.90). In BR.21, there was a trend for patients in the statin cohort to have an improved OS and DSS (data not shown), compared with the no-statin cohort (OS: HR ¼ 0.69, log rank P ¼ 0.098; DSS: HR ¼ 0.62, log rank P ¼ 0.048).
To explore this further, the outcome of patients on statins randomized to the erlotinib and placebo arm was evaluated separately. These analyses were limited by the small number of patients on statins in both arms (n ¼ 23 and n ¼ 5, respectively); however, for patients in the statin cohort randomized to the erlotinib arm, there was a nonsignificant trend for improvement in OS (HR ¼ 0.82, log rank P ¼ 0.43) and DSS (HR ¼ 0.72, log rank P ¼ 0.20) (Figure 7b ) compared with patients not on statins. However, the statin cohort randomized to the placebo arm of BR21 also had a nonsignificant improvement, although the significance of this is uncertain as only five patients were examined.
Discussion
In this study, we are the first to show that the inhibitory effects of lovastatin on EGF-induced EGFR activation , geranylgeranyl diphosphate (GGPP), dolichol and ubiquinone were coadministered with lovastatin to determine the metabolites of this pathway that could reverse the inhibitory effects of lovastatin on EGFR activity. Western blot analysis of 10 mM lovastatin-treated SCC9 cells for 24 h alone and coincubated with 100 mM mevalonate, 10 mM GGPP, 10 mM FPP, 10 mM dolichol phosphate or 10 mM ubiquinone was performed. Before protein extraction, all cultures were exposed to 50 ng EGF for 30 min. Total EGFR expression (upper panel) was evaluated, as well as total phosphotyrosine levels of EGF-stimulated EGFR (PY20) and phosphorylation of the 1068 tyrosine residue of the EGFR. Densitometric analyses of the phosphorylation levels of the 1068 tyrosine residue of the EGFR normalized to the levels of total EGFR were performed. (b) Western blot analysis of 10 mM lovastatin-treated SCC9 or SCC25 cells (except lane 1, 2, 5 and 7) for 24 h alone and coincubated with 100 mM mevalonate or 10 mM GGPP was performed. Before protein extraction, cells were exposed to 50 ng EGF for 30 min as indicated. Cells were washed with ice-cold PBS and incubated on ice for 30 min with the crosslinking reagent bis(sulfosuccinimidyl)suberate (3 mM in PBS). Dimers were visualized as 4300 kD bands.
were because of its ability to inhibit receptor dimerization. The inhibitory effects of lovastatin on EGFR dimerization were mediated through targeting of the mevalonate pathway. Furthermore, lovastatin has significant effects on SCC actin architecture, and inhibiting rhoA similarly affected EGFR dimerization and activation. Actin organization has been shown to have a role in EGFR localization and activation (Lunn et al., 2000) . This represents a novel mechanism by which lovastatin regulates this important therapeutic target. In a number of malignancies, including SCC, EGFR and its downstream signaling pathways are often deregulated, leading to cell hyperproliferation, enhanced cell survival and increased metastatic potential (Nicholson et al., 2001) . Of particular importance in cancer therapy is the hyperactivation of the PI3K/AKT pathway that regulates cell survival, cellular metabolism and protein translation (Dann and Thomas, 2006) . In this study, we confirmed that lovastatin treatment inhibits EGFinduced AKT activation and its targets that regulate protein translation SP6 and 4EBP-1 (Dann and Thomas, 2006) . SCC patients have very limited treatment options when presenting with metastatic disease (Greenlee et al., 2000) and inhibitors of EGFR have limited therapeutic efficacy. Using EGFR-targeting agents requires combination-based therapies to enhance their clinical activity. Our recent studies have shown that the depletion of mevalonate metabolites affects the activity of a number of cell signaling cascades, including inhibitory effects on EGFR activity and their downstream signaling pathways (Mantha et al., 2005; Niknejad et al., 2007) . Combinations of statins with agents targeting EGFR activity, such as gefitinib, induce a potent synergistic cytotoxic response in a variety of responsive tumor types, including SCC (Mantha et al., 2005) . Combining these two approaches, with each targeting the EGFR through distinct mechanisms, represents a novel combinational therapeutic approach in SCC, as well as in other cancers in which EGFR is involved in their pathogenesis (Dimitroulakos et al., 2006) . Rationally designed combination therapies represent a potential strategy to improve their efficacy. On the basis of the data presented herein, we show that lovastatin is a potent inhibitor of AKT activation by targeting EGFR in a novel inhibitory mechanism and may represent a Western blot analysis of rhoA, rac1 and cdc42 protein expression levels in lovastatin-treated SCC9 and SCC25 cell lines for 24 h. Treatment with 100 mM mevalonate or 10 mM GGPP with or without 20 mM lovastatin was also evaluated. Expression levels of actin were assayed as the loading control. (c) Western blot analysis of cyclinD1 expression levels in 10-50 mM lovastatin-treated SCC9 and SCC25 cell lines for 24 h. In SCC25 cells, treatment with 100 mM mevalonate or 10 mM GGPP with or without 20 mM lovastatin was also evaluated. Expression levels of actin were assayed as the loading control. (d) Two-dimensional gel electrophoresis of SCC9 cells treated with control and 25 mM lovastatin for 24 h. After isoelectric focusing, protein extracts were western blotted for expression of rhoA. Equal concentrations of total protein were used for each condition. (e) RhoA activation assay. Serum-starved SCC9 and SCC25 cells were treated with 10 mM lovastatin, 100 mM mevalonate and 10 mM GGPP alone and in combination, as indicated for 24 h. Cells were stimulated with EGF for 30 min as indicated and assayed for rhoA activity using the RhoA G-LISA kit that quantifies activated GTP-loaded rhoA through colorimetric detection of rhoA bound to Rho-guanosine-5 0 -triphosphate-binding protein. novel combinational therapeutic approach in combination with EGFR-tyrosine kinase inhibitors. To evaluate the feasibility of this approach, although not statistically significant, we showed that erlotinib-treated patients in the BR21 phase III trial with statin use showed a trend toward enhanced OS and DSS compared with patients with no statin use. Although these data are intriguing, interpretation of these results is limited because of the small number of patients on statin therapy. Furthermore, it is not possible to determine whether statin use has prognostic implications, or whether patients on statin and erlotinib have an increased benefit compared with being on erlotinib alone. This requires further evaluation in another independent data set and/or a prospectively designed clinical trial. In fact, on the basis of our studies, we are currently evaluating erlotinib and rosuvastatin in a phase I/II clinical trial in NSCLC patients at our institute (ClinicalTrials.gov Identifier: NCT00966472) to address the potential clinical benefit of this approach. In this study, we have shown the ability of lovastatin to inhibit ligand-induced receptor dimerization, internalization, autophosphorylation and AKT activation. Depletion of geranylgeranylated proteins because of inhibition of mevalonate pathway end products by lovastatin leads to actin disorganization, and is likely the mechanism that regulates lovastatin's inhibition of receptor tyrosine kinase activity and its downstream effects. The ability of lovastatin to inhibit EGFR dimerization and internalization is intriguing and requires further study to elucidate its mechanism and possible clinical implications.
Materials and methods
Tissue culture SCC9 and SCC25 HNSCC cell lines were obtained from the American type culture collection (ATCC, Rockville, MD, USA). The NIH 3T3 cell line was provided by Dr D Gray (Ottawa Hospital Research Institute, Ottawa, ON, Canada). The cell lines were maintained in Dulbecco's-MEM (Media Services, Ottawa Regional Cancer Centre) supplemented with 10% fetal bovine serum (Medicorp, Montreal, Canada) . A 50mg/ml stock solution of human recombinant EGF (Sigma, St Louis, MI, USA) was diluted in 10 mM acetic acid/0.1% bovine serum albumin (Sigma). Lovastatin (provided by Apotex, Mississauga, ON, Canada), mevalonate, GGPP, FPP, dolichol and ubiquinone (all from Sigma) were used as previously described (Dimitroulakos et al., 2002) . Gefitinib (provided by AstraZeneca, Macclesfield, England), rapamycin (Sigma), Y-27632 (Calbiochem, San Diego, CA, USA) and sodium orthovanadate (Na 3 OV 4 ; Sigma) were reconstituted in dimethyl sulfoxide (Sigma).
Western blot analysis
Total cellular protein was extracted using radioimmunoprecipitation assay buffer containing protease inhibitor cocktail (Sigma). Protein extracts representing 50-100 mg of total protein were separated on a 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis gel (unless otherwise stated) and western blots were performed as previously described (Mantha et al., 2005) . The primary antibodies used were specific for phospho-AKT, AKT, phospho-S6K1, S6K1, phospho-4EBP1, 4EBP1, EGFR (Cell Signaling Technology, Danvers, MA, USA); phosphotyrosine (clone PY20), rhoA, rac1, cdc42, cyclinD1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA); EGFR, pEGFR 1068 (Cell Signalling Technology); and actin (Sigma). The secondary antibodies (Amersham Biosciences, Baie d'Urfe, Canada) were used at a 1:5000 dilution. The images were acquired using the Gene Gnome Imaging System (Syngene Bio-imaging, Frederick, MD, USA). Figure 7 Analysis of statin use in disease-specific survival in patients enrolled in the BR18 (carboplatin/paclitaxel ± BMS275291) and BR21 (erlotinib) phase III clinical trials. Kaplan-Meier curves for OS and DSS comparing statin use to no-statin use in the BR18 (a) and BR21 (b) clinical trials. Hazard ratios were determined and the log-rank test for significance was performed. In erlotinib-treated patients in the BR21 trial, statin use seemed to provide enhanced OS and DSS compared with patients with no-statin treatments.
Receptor dimerization and cell surface expression Cells were washed with ice-cold phosphate-buffered saline (PBS) and incubated on ice for 30 min with the crosslinking reagent bis(sulfosuccinimidyl)suberate (3 mM in PBS, Pierce; Sorkin and Carpenter, 1991; Sorokin et al., 1994) . Dimers were visualized using western blot analysis as 4300 kD bands, in which monomers served as loading control. The Pinpoint Cell Surface Protein Isolation Kit (Pierce, Rockford, IL, USA) was used to isolate proteins expressed on the cell surface. In brief, SCC9 cells treated for 24 h with control and 10 mM lovastatin were stimulated with or without 50 ng/ml of EGF for 30 min. Cells were then washed with ice-cold PBS and surface proteins were biotinylated and isolated using immobilized avidin and assayed for EGFR expression by western blot analysis.
Polysome fractionation
To isolate polysomes, cells were treated as previously described (Blais et al., 2004) with 500 ml of cell lysate layered on a continuous sucrose gradient (10-50% sucrose in 15 mM MgCl2, 15 mM Tris pH 7.4, 0.3M NaCl). Absorbance of the gradients was measured continuously at 254 nm from top to bottom at a flow rate of 1 ml/min collected in 12 fractions of 1 ml. RNA was extracted by phenol chloroform extraction and an equal volume from each fraction was used to perform realtime reverse transcriptase PCR. Quantitative real-time PCR was performed using the QuantiTect SYBR green PCR kit (Qiagen, Mississauga, ON, Canada) with the ABI Prism 7500 system (Applied Biosystems, Foster City, CA, USA) with ABI Prism 7500 SDS Software. Standard curves of each primer set were conduced to determine the relative amount of mRNA in each fraction. The sum of mRNAs from fractions 1-5 or 6-10 was divided by total mRNAs in all 10 fractions to give the percentage representation. The primers for gene-specific reverse transcriptase PCR analysis were as follows: ATF3 TAGGCTG GAAGAGCCAAAG (5 0 ) and TTCTCACAGCTGCAAA CACC (3 0 ); Gapdh TTGATGTCATCATACTTGGCAGGT (5 0 ) and CAGTCAAGGCTGAGAATGGGA (3 0 ).
Two-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis After treatment, cells were collected and washed in ice-cold sucrose buffer (10 mM BES pH 7.4, 0.3M sucrose) and lysed in IEF buffer (7 M urea, 2 M thiourea, 4% CHAPS, 65 mM dithiothreitol and 0.0001% bromophenol blue, all from Sigma) and homogenized by vortexing for 1.5 h. Proteins were then precipitated by addition of 10 volumes of acetone (Sigma), followed by a 2500 r.p.m. centrifugation for 5 min. Pellets were resuspended in IEF buffer plus 0.4% 3-10 ampholytes (BioRad, Mississauga, ON, Canada), and protein concentrations were determined by Bradford Assay (Bio-Rad). IPG strips (7 cm, 3-10 pH range, Bio-Rad) were rehydrated overnight with 50 mg of total protein in a total volume of 125 ml. Isoelectric focusing was carried out with the following conditions: 250 V for 20 min, 4000 V for 2 h for desalting and 10 000 Vh at 4000 V for focusing. Strips were then equilibrated for 15 min in reducing (6M urea, 375 mM Tris-HCl ph 8.8, 20% glycerol, 2% sodium dodecyl sulfate, 130 mM DTT) and alkylating buffers (6M urea, 375 mM Tris-HCl pH 8.8, 20% glycerol, 2% sodium dodecyl sulfate, 216 mM iodoacetamide) before running the second dimension on a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel.
Phalloidin staining and immunofluorescence
In a six-well tissue culture dish (Fisher, Mississauga, ON, Canada), B50 000 cells were used to seed each well containing a 1 Â 1 cm glass coverslip (Fisher). Following treatments, cells were fixed for 15 min in 4% PBS-buffered paraformaldehyde (Sigma) at 37 1C. The cells were then permeabilized using 0.1% Triton X-100 (Sigma) in PBS for 15 min. To label the actin cytoskeleton, cells were incubated with rhodamine-conjugated phalloidin (Sigma; 1 mg/ml in PBS) for 15 min at room temperature. For immunofluorescence, cells were blocked with 3% fetal bovine serum in PBS for 30 min. The primary antibody (EGFR) was added at a 1:50 dilution in 3% fetal bovine serum in PBS for 1 h, followed by 3 Â PBS washes. The secondary rhodamine-labeled antibody (Calbiochem) at a 1:50 dilution in 3% fetal bovine serum in PBS was then incubated for 1 h. After two washes in PBS, the slides were mounted with a 4 0 -6-diamidino-2-phenylindole-containing immunofluorescent mounting media (Vector Laboratories, San Diego, CA, USA). For EGF and transferrin staining, fluorescein isothiocyanate-conjugated EGF (Molecular Probes, Carlsbad, CA, USA) and rhodamine-conjugated transferrin (Molecular Probes) both at 50 ng/ml were added to cells 15 min before fixation as described above. After two PBS washes, the slides were mounted and viewed by immunofluorescent microscopy as described above.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay In a 96-well, flat-bottomed plate (Fisher), B7500 cells per 150 ml of cell suspension were used to seed each well. Cells were pretreated with control media, 10 nM rapamycin or 10 mM lovastatin for 24 h, followed by a 48 h treatment of gefitinib and assayed for 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide activity as previously described (Mantha et al., 2005) . Treatments were performed in replicates of six and the means were expressed as the percentage viability relative to the untreated control (100% viable).
RhoA activity assay SCC9 and SCC25 cell lines were cultured in serum-free media treated with 10 mM lovastatin for 24h with or without 100mM mevalonate or 10 mM GGPP. Cells were stimulated with 50 ng/ml of EGF for 30 min to activate rhoA. Cell lysates were either snap frozen and stored in liquid nitrogen or used directly with the RhoA G-LISA kit (Cytoskeleton, Denver, CO, USA) according to the manufacturer's instructions. The degree of rhoA activation is determined by comparing readings from the activated cell lysates (addition of 0.2 mM guanosine-5 0 -triphosphate) versus the nonactivated cell lysates (serum-starved cultures).
Evaluating the impact of statin use in BR. 18 and BR.21 The association between statin use and OS and DSS of patients with advanced NSCLC was evaluated from the databases of two NCIC Clinical Trials Group trials. Using the BR.21 and BR.18 databases, patients on statin therapy were identified. Kaplan-Meier curves, stratified by treatment, were generated to assess the OS and DSS of the statin cohort versus the nonstatin cohort in both trials. OS was defined as the time from randomization to death from any cause and DSS was defined as the date from randomization to date of death from NSCLC and/or related to NSCLC treatment. A Cox regression model was used to assess the association of statin use with OS and DSS adjusted for baseline variables.
Abbreviations DSS, disease specific survival; EGFR, epidermal growth factor receptor; FPP, farnesyl pyrophosphate; GGPP, geranylgeranyl pyrophosphate; NSCLC, non-small-cell lung carcinoma; OS, overall survival; ROCK, rho-associated kinase; SCC, squamous cell carcinoma.
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